News articles about Omeros (NASDAQ:OMER) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Omeros earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.1937679989377 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Omeros (NASDAQ:OMER) traded up $0.19 during midday trading on Wednesday, reaching $11.14. The company’s stock had a trading volume of 405,980 shares, compared to its average volume of 1,098,745. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $27.09. The company has a debt-to-equity ratio of -29.93, a current ratio of 4.12 and a quick ratio of 4.10. The company has a market cap of $529.48, a price-to-earnings ratio of -9.19 and a beta of 3.57.
Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). The firm had revenue of $13.76 million during the quarter, compared to analysts’ expectations of $21.94 million. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.45) EPS. sell-side analysts expect that Omeros will post -0.76 EPS for the current fiscal year.
WARNING: This report was first published by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-omeros-omer-stock-price/1973384.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.